July 4, 2017 / 5:14 AM / 2 months ago

BRIEF-Cadila Healthcare says Zydus' combination drug for diabetes gets tentative FDA nod

July 4 (Reuters) - Cadila Healthcare Ltd:

* Says Zydus receives tentative approval from U.S.FDA for sitagliptin and metformin hydrochloride tablets

* Says the fixed dosed combination is indicated for type 2 diabetes mellitus

* Sitagliptin, metformin hydrochloride tablets will be produced at group's formulations manufacturing facility at pharma SEZ, Ahmedabad Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below